InsiderSignal.AI

InsiderSignal.ai

ROIV - Roivant Sciences Ltd.

Insider Sale by Venker Eric (Pres, Immunovant CEO)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

1 week ago, Venker Eric, serving as Pres, Immunovant CEO at Roivant Sciences Ltd. (ROIV), sold 200,000 shares at $26.49 per share, for a total transaction value of $5,298,000.00. Following this transaction, Venker Eric now holds 1,654,597 shares of ROIV.

This sale represents a 11.00% decrease in Venker Eric's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Friday, February 13, 2026 and publicly disclosed via SEC Form 4 filing on Wednesday, February 18, 2026, 5 days after the trade was made.

Roivant Sciences Ltd. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Venker Eric

Pres, Immunovant CEO

Eric Venker, M.D., Pharm.D., is the President of Roivant Sciences Ltd. (NASDAQ: ROIV) and Chief Executive Officer of its subsidiary Immunovant.[[1]](https://www.investing.com/news/insider-trading-news/roivant-sciences-president-venker-sells-404-million-in-shares-93CH-4344271)[[2]](https://fintool.com/app/research/companies/ROIV/people/eric-venker)[[5]](https://www.roivant.com/about/leadership) He joined Roivant in 2014, previously serving as President and COO before his current roles.[[2]](https://fintool.com/app/research/companies/ROIV/people/eric-venker)[[4]](https://www.nasdaq.com/articles/immunovant-announces-leadership-changes-eric-venker-appointed-ceo-and-tiago-girao-cfo)[[5]](https://www.roivant.com/about/leadership) Dr. Venker has been actively involved in recent insider trading activities, including selling 200,000 shares on November 7, 2025, for $4.04 million after exercising options, and another 200,000 shares on January 12, 2026.[[1]](https://www.investing.com/news/insider-trading-news/roivant-sciences-president-venker-sells-404-million-in-shares-93CH-4344271)[[3]](https://www.tradingview.com/news/tradingview:6d066f8976c8c:0-roivant-sciences-executive-sells-200-000-shares/) His leadership aligns with Roivant's advancements, such as positive Phase 3 trial results for brepocitinib in dermatomyositis.[[1]](https://www.investing.com/news/insider-trading-news/roivant-sciences-president-venker-sells-404-million-in-shares-93CH-4344271)

View full insider profile →

Trade Price

$26.49

Quantity

200,000

Total Value

$5,298,000.00

Shares Owned

1,654,597

Trade Date

Friday, February 13, 2026

9 days ago

SEC Filing Date

Wednesday, February 18, 2026

Filed 5 days after trade

HEALTHCAREBIOTECHNOLOGY

About Roivant Sciences Ltd.

Company Overview

No company information available
View news mentioning ROIV

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/4097951

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime